FDA approves landmark pancreatic cancer drug that's shown to improve survival

The FDA has granted expedited approval to daraxonrasib, a new pill targeting KRAS mutations, doubling median survival for patients with advanced pancreatic cancer and offering treatment where few options existed.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.